Skip to content
DataLookout
Menu

NCT02775500

Apremilast Pregnancy Exposure Registry

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 6 versions: 4 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Jul 2025 to May 2027
  2. Notable Primary completion date changed from estimate of Apr 2024 to Dec 2024v6
  3. Notable Primary completion date: Feb 2022 to Apr 2024v5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 300 to confirmed 233
    • Study completion date: Jul 2024 to Jul 2025
    • Site details revised
  4. Notable Primary completion date: Feb 2021 to Feb 2022
    • Study completion date: Jul 2021 to Jul 2024
    v3
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The number of major structural malformations identified in the children of study participants
Timeframe: Throughout pregnancy through 1 year of life
A pattern of major malformations identified in the children of study participants
Timeframe: Throughout pregnancy through 1 year of life

Secondary (8)

Pattern of minor structural malformations identified by study physical exam in the children of study participants
Pregnancy Outcome; rate of live born infants, spontaneous abortions, stillbirths, and terminations between cohort groups
Gestational age at delivery among infants in the cohort groups
Pregnancy Complication rates between cohort groups
Neonatal Complication rates between cohort groups
Show 3 moreShow less
Pre- and post-natal fetal and infant growth percentiles
Any serious and opportunistic infections rates occurring in infants whose mothers are enrolled in the study
Any malignancies diagnosed in infants of mothers enrolled in the study

Arms and interventions

Apremilast-Exposed Cohort

Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.

Diseased Comparison Cohort

Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.

Healthy Comparison Cohort

Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.

Apremilast-Exposed Registry Group

Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.

Drugs: apremilast

Sites

1 site in 1 country

  • University of California, San DiegoLa Jolla, California, United States